Global Financial Private Client’s CRISPR Therapeutics CRSP Stock Holding History

Global Financial Private Client’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23	Closed	-$783	–	527
2025 Q1	$783	Hold	23	–	–	﹤0.01%	1131
2024 Q4	$905	Hold	23	–	–	﹤0.01%	798
2024 Q3	$1.08K	Hold	23	–	–	﹤0.01%	754
2024 Q2	$1.24K	Hold	23	–	–	﹤0.01%	608
2024 Q1	$1.57K	Hold	23	–	–	﹤0.01%	610
2023 Q4	$1.44K	Buy	+23	New	+$1.27K	﹤0.01%	607

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Global Financial Private Client's CRSP Position: Q2 2025 in Review

Global Financial Private Client sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 23 shares — an estimated $783 sold.

Global Financial Private Client first reported a position in CRSP in Q4 2023 and held it in 6 quarters. The position peaked at $1.57K in Q1 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Global Financial Private Client reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
Global Financial Private Client sold 23 CRISPR Therapeutics shares in Q2 2025, an estimated $783.
Global Financial Private Client first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 6 quarters.
Global Financial Private Client's CRISPR Therapeutics position peaked at $1.57K in Q1 2024.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.